Non-invasive low-risk passes generally do not require amniocentesis, but it depends on the circumstances.
Non-invasive prenatal testing (NIPT) is a prenatal screening tool used for secondary screening of high-risk groups, such as high risk of Down’s syndrome and pregnant women of advanced age, which can screen for the risk of three types of chromosomal disorders, namely, trisomy 21, trisomy 18 and trisomy 13, with a high degree of accuracy.
Amniocentesis is usually not needed when the results are low risk, but it is still needed when the fetus is at risk for other chromosomal disorders, for example.
Amniocentesis is one of the prenatal diagnostic methods, which can extract amniotic fluid and then conduct chromosomal karyotyping, gene and gene product testing to confirm the diagnosis of fetal chromosomal disorders and genetic disorders, etc. It needs to be operated by specialized doctors.
After the procedure, it is necessary to take proper rest and pay attention to tracking the results in order to clarify the diagnosis in time and intervene as early as possible to ensure the quality of the fetus.